New shot at beating hepatitis b? experimental drug trial seeks to lower virus levels
NCT ID NCT02604212
Summary
This study tested whether adding an experimental drug called ARC-520 to standard hepatitis B medications could better reduce the amount of virus in the body. About 32 adults with a specific type of chronic hepatitis B received either ARC-520 or a placebo injection alongside their regular pills. The main goal was to see if the combination was safe and could lower hepatitis B surface antigen levels more than standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Hong Kong, 999077, China
-
Research Site 10
Leipzig, 04103, Germany
-
Research Site 11
Frankfurt, 60590, Germany
-
Research Site 12
Yangsan-si Gyeongnam, 626-770, South Korea
-
Research Site 13
Busan, 602-739, South Korea
-
Research Site 14
Seoul, 110-744, South Korea
-
Research Site 15
Incheon, 405-760, South Korea
-
Research Site 16
Seoul, 120-752, South Korea
-
Research Site 2
Hong Kong, China
-
Research Site 3
Tübingen, 72076, Germany
-
Research Site 4
Leipzig, 4103, Germany
-
Research Site 5
München, 81377, Germany
-
Research Site 6
Ulm, 89081, Germany
-
Research Site 7
Würzburg, 97080, Germany
-
Research Site 8
Hanover, 30625, Germany
-
Research Site 9
Hamburg, 20099, Germany
Conditions
Explore the condition pages connected to this study.